Zapping Away The Blues

A pacemakerlike device to treat depression takes a giant step forward

4 min read

This month Cyberonics Inc., in Houston, plans to introduce the first implanted device that can treat a psychiatric illness. The implant, when used in combination with standard therapies, can alleviate the symptoms of chronic or recurrent depression in the 20 percent of patients who do not benefit from Prozac, Paxil, and other drugs.

Some 11 million such treatment-resistant patients live in the developed world, more than 4 million of them in the United States. At press time, Cyberonics was working to meet the U.S. Food and Drug Administration's conditions for the implant's approval. A nerve stimulator, the implant is already used to treat depression in Canada and the European Union.

Keep Reading ↓Show less

This article is for IEEE members only. Join IEEE to access our full archive.

Join the world’s largest professional organization devoted to engineering and applied sciences and get access to all of Spectrum’s articles, podcasts, and special reports. Learn more →

If you're already an IEEE member, please sign in to continue reading.

Membership includes:

  • Get unlimited access to IEEE Spectrum content
  • Follow your favorite topics to create a personalized feed of IEEE Spectrum content
  • Save Spectrum articles to read later
  • Network with other technology professionals
  • Establish a professional profile
  • Create a group to share and collaborate on projects
  • Discover IEEE events and activities
  • Join and participate in discussions

With This Bionic Nose, COVID Survivors May Smell the Roses Again

A decades-long quest pairs an e-nose with a brain implant

12 min read
Two scientists in white lab coats look at a mannequin head that’s wearing a pair of black glasses with wires sticking out from several places. One of the scientists holds up a small vial of blue liquid to the wire above the bridge of the nose. A vial of purple liquid sits on the table.

Richard Costanzo [left] and Daniel Coelho [right] demonstrate the external components of their olfactory prosthetic. In a complete system, after the sensor detects an odor, the transmitter would send a signal to a stimulator implanted in the brain.

DeAudrea 'Sha' Aguado
LightBlue

Richard Costanzo stands beside a mannequin head sporting spectacles decked with electronics and holds a vial of blue liquid up to a tiny sensor. An LED glows blue, and Costanzo’s phone displays the word “Windex.” Then he waves a vial of purple liquid and gets a purple light along with the message “Listerine.”

“There won’t be Scotch tape on the final model,” says Costanzo, as he rearranges the gear in his lab at Virginia Commonwealth University (VCU), in Richmond. The prototype is a partial demonstration of a concept that he’s been working on for decades: a neuroprosthetic for smell. The mannequin represents someone who has lost their sense of smell to COVID-19, brain injury, or some other medical condition. It is also intended to show off the sensor, which is the same type used for commercial electronic noses, or e-noses. In the final product, the sensor won’t light up an LED but will instead send a signal to the user’s brain.

Keep Reading ↓Show less
{"imageShortcodeIds":["31947120"]}